Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 6, 2015

Primary Completion Date

December 10, 2024

Study Completion Date

December 17, 2024

Conditions
Chronic Lymphocytic Leucemia
Interventions
DRUG

Bendamustine

Debulking: Cycles 1-2, d1 \& 2: 70mg/m² i.v.

DRUG

GA101

Induction: Cycle 1: d1: 100mg, d1(or 2): 900mg, d8 \& 15: 1000mg; Cycle 2-6: d1: 1000mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1: 1000mg

DRUG

ABT-199

Induction: Cycle 2: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg; Cycle 3-6: d1-28: 400mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84: 400mg

Trial Locations (1)

50935

German CLL Study Group, Cologne

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

AbbVie

INDUSTRY

lead

German CLL Study Group

OTHER